Palvella Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases for which there are no FDA-approved therapies. It is developing a pipeline of innovative treatments for rare genetic skin diseases using its patented QTORIN platform. The company was founded on December 13, 2024 and is headquartered in Wayne, PA.